
Going after an old GSK target in a new way, a Yale spinout hits the clinic and nabs a modest raise
About a year and a half ago, a Yale professor took a shot at engineering a cancer therapy that had once flummoxed researchers at GlaxoSmithKline. The company announced its next steps Thursday, earning a modest fundraise and entering the clinic.
Simcha Therapeutics closed a $40 million Series B and has begun dosing patients in a Phase I/II trial for its lead program, the biotech announced. The raise should take Simcha into 2024 and help complete the just-launched Phase I portion, a Phase II monotherapy study and a Phase Ib combination trial with a checkpoint inhibitor, founder Aaron Ring told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.